Use of cannabidiol in the treatment of autism, review of the literature and future perspectives
DOI:
https://doi.org/10.33448/rsd-v13i3.41741Keywords:
Autism Spectrum Disorder; Cannabis sativa; Pharmacological treatment; Receptors.Abstract
Autism Spectrum Disorders (ASD) are considered a multifactorial disease, being associated with genetic and non-genetic causes with a predominance of development in early childhood and that compromises the cognitive, social and affective spheres, in addition to physical growth itself. There are no specific medications for autism and several medications are used to alleviate the symptoms associated with ASD, in addition there is much discussion about the use of cannabidiol. This work is a systematic review of the literature with the aim of understanding more about the use of cannabidiol to help treat patients with ASD. The results found demonstrate a strong relationship between TEA and the endocannabinoid system, especially in the CB1 and CB2 receptors. Most of the works show that the use of cannabidiol brought more benefits than side effects or adverse reactions, acting mainly in the improvement of the signs and symptoms of ASD. Therefore, it is concluded that it is of great importance to carry out more studies to clarify points that are still obscure in the use of cannabidiol in the treatment of ASD.
References
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022). An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics, 19(1), 248–262. https://doi.org/10.1007/s13311-022-01183-1
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X. (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism, 12(1), 1–11. https://doi.org/10.1186/s13229-021-00420-2
Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019). Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Scientific Reports, 9(1), 1–7. https://doi.org/10.1038/s41598-018-37570-y
Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., Koren, G., & Berkovitch, M. (2019). Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and Co-morbidities. Frontiers in Pharmacology, 9(JAN), 1–5. https://doi.org/10.3389/fphar.2018.01521
Chayasirisobhon, S. (2019). Cannabis and neuropsychiatric disorders: An updated review. Acta Neurologica Taiwanica, 28(2), 27–39.
SIlva Junior, E. A. (2020). Avaliação Da Eficácia E Segurança Do Extrato De Cannabis Rico Em Canabidiol Em Crianças Com O Transtorno Do Espectro Autista: “Ensaio Clínico Randomizado, Duplo-Cego E Placebo Controlado.” 149.
Ferreira, C. I. R. (2020). Etiologia e Fisiopatologia da Perturbação do Espetro do Autismo-Revisão Narrativa da Literatura. 36.
Fleury-Teixeira, P., Caixeta, F. V., Da Silva, L. C. R., Brasil-Neto, J. P., & Malcher-Lopes, R. (2019). Effects of cbd-enriched cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use. Frontiers in Neurology, 10(OCT), 1–9. https://doi.org/10.3389/fneur.2019.01145
Howlett, A., Blume, L., & Dalton, G. (2010). CB1 Cannabinoid Receptors and their Associated Proteins. Current Medicinal Chemistry, 17(14), 1382–1393. https://doi.org/10.2174/092986710790980023
Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., Garner, J. P., Hardan, A. Y., & Parker, K. J. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9(1), 1–6. https://doi.org/10.1186/s13229-018-0203-y
Lima, L. R., Alencar, G. S. B. C., Dutra, T. C. G., Bezerra, C. M. F. M. C., Lima, J. B., Gusmao, E. E. S., Costa, E. L., Silva, A. C. V., Trabulsi, R. K., Nicolau, A. D. M. F., Lopes, A. S. V., & New York, B. B. C. C. (2023). Avaliação dos benefícios do uso de canabidiol no tratamento de indivíduos com Transtorno do Espectro Autista (TEA). Brazilian Journal of Health Review, 6(4), 17665–17680. https://doi.org/10.34119/bjhrv6n4-284
MostafavI, M., & Gaitanis, J. (2020). Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience. Seminars in Pediatric Neurology, 35, 100833. https://doi.org/10.1016/j.spen.2020.100833
Oliveira, A. D. C., & Pottker, C. A. (2019). Considerações Sobre O Canabidiol No Processo Psicoterapêutico De Crianças Com Transtorno Do Espectro Autista. Revista UNINGÁ Review, 34(4), 24–37. https://doi.org/10.46311/2178-2571.34.4.024-037
Oliveira, C. R.A., & Souza, J. C. (2021). Neurobiologia do autismo infantil. Research, Society and Development, 10(1), e11910111495. https://doi.org/10.33448/rsd-v10i1.11495
Organización Pan-americana de la Salud - OPAS (2024, 08 de febrero). https://www.paho.org/pt/topicos/transtorno-do-espectro-autista#:~:text=Estima%2Dse%20que%2C%20em%20todo
Poleg, S., Golubchik, P., Offen, D., & Weizman, A. (2019). Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 89, 90–96. https://doi.org/10.1016/j.pnpbp.2018.08.030
Pretzsch, C. M., Voinescu, B., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Williams, S., Murphy, D. G. M., Daly, E., & Mcalonan, G. M. (2019). The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, 33(9), 1141–1148. https://doi.org/10.1177/0269881119858306
Silva, W. M., & Coelho, A. T. C. B. (2021). O processo de aquisiçao de linguagem para a criança com transtorno do espectro autista: artigo de revisão. Research, Society and Development, 10(1), e15010111584. https://doi.org/10.33448/rsd-v10i1.11584
Wei, D., Lee, D. Y., Cox, C. D., Karsten, C. A., Penagarikano, O., Geschwind, D. H., Gall, C. M., & Piomelli, D. (2015). Endocannabinoid signaling mediates oxytocin-driven social reward. Proceedings of the National Academy of Sciences of the United States of America, 112(45), 14084–14089. https://doi.org/10.1073/pnas.1509795112
Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. International Journal of Molecular Sciences, 18(9), 1–14. https://doi.org/10.3390/ijms18091916
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jean Colacite; Nicole Melo Calixto; Lais Picinin Bittencourt Rech; Luana Silva Campos; Isabela Pedro Lopes Ferreira; José Orlando Cubas Filho; Liamara Lezan; Andres Alexander Florentin; Paula Bueno Castanho; Carol Andrea Oliveros
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
